Quantitative US for Hepatic Steatosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

124 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-05

Study Completion Date

2020-01-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the diagnostic performance of quantitative ultrasound imaging parameter for the assessment of hepatic steatosis in patients with non-alcoholic fatty liver disease using magnetic resonance imaging proton density fat fraction (MRI-PDFF) and MR spectroscopy as the reference standard.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Quantitative US for Evaluation of Hepatic Steatosis in NAFLD

NCT04462562

Fatty Liver Fatty Liver, Nonalcoholic

COMPLETED NA

Quantitative Ultrasound for Diagnosing Hepatic Steatosis in Nonalcoholic Fatty Liver Multicenter Study

NCT04985188

Diagnoses Disease

UNKNOWN

Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD

NCT07192159

Metabolic Dysfunction-Associated Steatotic Liver Disease Hepatic Steatosis Liver Disease Parenchymal

RECRUITING NA

Usefulness of Ultrasound-derived Fat Fraction for Quantification of Hepatic Steatosis in Patients Suspected of MASLD

NCT06662851

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease

ACTIVE_NOT_RECRUITING

Quantitative CT Imaging Parameters for Assessing Hepatic Steatosis in CHB

NCT06616103

Chronic Hepatitis B Steatosis of Liver Fibrosis and Cirrhosis of Liver

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Steatosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Quantitative ultrasound imaging parameter

Quantitative ultrasound imaging parameter (QUS)

Group Type EXPERIMENTAL

Quantitative ultrasound imaging parameter (QUS)

Intervention Type DIAGNOSTIC_TEST

Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quantitative ultrasound imaging parameter (QUS)

Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with clinically suspected non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), or living-donor candidates for liver transplantation, or volunteers
* Signed informed consent

Exclusion Criteria

* chronic liver disease patients (serum HBsAg positive or anti-hepatitis C virus (HCV), histologic confirmation)
* chronic alcoholics
* serum alanine transaminase (ALT)\>5 times the upper limit of normal within 3 months
* previous liver surgery
* acute hepatitis or bile duct obstruction

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes